Availability of Data and Material (Data Transparency)
Institutional quality improvement approval was obtained prior to data review and manuscript preparation.
Funding
The authors acknowledge philanthropic support from Ben-Liou Yao and Amy Chen.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
AW reports that her institution, Brigham and Women's Hospital, has a sponsored research agreement with Myriad Laboratories, Inc. EAM reports compensated service on scientific advisory boards for AstraZeneca, Exact Sciences, Merck, and Roche/Genentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly, and Roche/Genentech; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. EAM reports the following nonfinancial interests, nonremunerated activities: Board of Directors for the American Society of Clinical Oncology and Scientific Advisor for Susan G. Komen for the Cure Foundation. TAK reports receiving speakers honoraria and compensated service on the scientific Advisory Board for Exact Sciences and compensated service from Besins Healthcare Global Advisory Board outside the submitted work. The remaining authors declare no conflicts of interest.
Ethics Approval
Institutional quality improvement approval was obtained prior to data review and manuscript preparation.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kantor, O., Weiss, A., Burstein, H.J. et al. ASO Visual Abstract: Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer with 1-3 Positive Sentinel Lymph Nodes. Ann Surg Oncol 29, 7683–7684 (2022). https://doi.org/10.1245/s10434-022-12081-3
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-12081-3